What proportion of antibodies used for detecting the GLP-1R exhibit high sensitivity and specificity? Sadly, very few, resulting in mis localization and misinterpretation of considerable data in the field https://t.co/62CVgJJpUr @Cell_Metabolism

Do GLP-1 medicine improve #psoriasis in people with #obesity independent of #weightloss The debate continues

Here intestinal fructose metabolism drives GLP-1 secretion required to potentiate insulin secretion, thereby establishing a gut-pancreas axis that counter-regulates fructose-induced hyperglycaemia. https://t.co/bWaXmtOPn2

SURMOUNT-OSA Weight loss drives a substantial proportion of benefit https://t.co/nsTq0WIbeL

Turns out that if you lose weight you feel better

RACK1 functions as a dual-compartment scaffold, assembling GCGR–PKA at the plasma membrane and PKAcα–CREB in the nucleus, enabling precise glucagon signaling and gluconeogenesis

In patients with Monoclonal Gammopathy of Unknown Significance (MGUS) and metabolic comorbidities, GLP-1 RA therapy was associated with significantly improved Progression Free and Overall Survival and reduced risk of progression to multiple myeloma

Surprise, or clinical validation of previous findings? 2009. Liraglutide reduces infarct size and death independent of weight loss or glycemic control in mice https://t.co/Q2V40T1Ydl HARMONY Outcomes Trial 2018 Lancet Albiglutide produces 22% reduction in MACE, <1% weight loss

Here the authors further support the link between #leptin signaling and tissue #fibrosis demonstrating that a leptin-neutralizing antibody may be a promising therapeutic approach for reducing fibrosis in the kidney, liver, lung, heart, and blood vessels

#VitaminD deficiency associates with increased risk for a broad range of medical conditions. Yet RCTs of Vitamin D replacement often fail to show therapeutic benefit. Here critical illness and risk of acute kidney injury https://t.co/qn2fcXC7HK @JCI_insight

Preclinical studies identify hypothalamic FSTL1 as a key mediator counteracting diet induced #obesity and provide a potential pharmacological strategy for obesity-related metabolic disorders #insulin sensitivity

In today’s #AI enabled academic world Fake it till you make it has a whole new vexatious meaning

https://t.co/eiMumZjYHK Excited to share our latest research @davykevinp @JohnSpeakman4 @Olalla_Prado @GuillermoZorri4 @BrendaDavy @VT_TBMH Link to full article https://t.co/6BacDl213u

Combined use of SGLT-2i and GLP-1RA for prevention of cardiorenal complications-A dynamic duo in #T2D care @DiabetologiaJnl https://t.co/dyQ0TphQdX

GLP-1 medicines reduce rates of stroke in PPL with #T2D Here, real world registry data on initiation of GLP-1 medicines after ischemic stroke. TGTBT?

Not your bartenders IPA, here reduction of gut inflammation by metabolic reprogramming of CD4+ T cells toward the enhancement of mitochondrial respiration. #microbiota

Studies of T cell acute lymphoblastic leukemia reveal that canagliflozin possesses potent anti-leukaemic effects underpinned by proliferative defects, cell cycle disruption and apoptosis, actions synergized by restriction of serine and glycine @MolMetab https://t.co/HOj4NdZIui

Introducing DOJE: The first U.S. memecoin ETF giving you spot exposure to Dogecoin via a traditional ETF.

Pemvidutide over 24 weeks in #MASLD A P2 dose ranging study showing significant reductions in hepatic steatosis

Multiple gene therapy approaches are being studied to take on the challenges of extending the duration of GLP-1 medicines. Should they be tunable and/or have a kill/off switch? https://t.co/4vXwKBlI4T

Insights from optogenetics in conjunction with hormone secretion measurements, electrophysiology, and cytoplasmic free Ca2+ concentration ([Ca2+]i) imaging to interrogate the relative roles of paracrine and electrical control of β-cells by δ-cells.

In this review the authors advocate for body weight independent mechanisms underlying the control of BP by GLP-1 medicines https://t.co/x86eHE5QIR #hypertension